ClinicalTrials.gg
TerminatedNCT04866056Updated Dec 1, 2022

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

A Phase 1/2 interventional study of Jaktinib and azacitidine in Myelodysplastic Syndromes, Myeloproliferative Neoplasms and Myelofibrosis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Corporate policy adjustments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 117 studies in Myelodysplastic Syndromes with a site in China — 55 open to participants now, 62 under way, 7 of them phase 3. Myelodysplastic Syndromes · China.

Enrollment
101st of 102
1 · median 76
Started
2021
with 12 others
Phase 1/2
21 of 117
10 open now
Registered
51st of 117
by date

Among the 117 studies in Myelodysplastic Syndromes with a site in China, this one is the 101st largest by enrollment of the 102 interventional ones that give a count, is one of 13 that started in 2021, is one of 21 in phase 1/2, and was the 51st registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

55 of the 117 studies in Myelodysplastic Syndromes with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Myelodysplastic Syndromes with a site in China, or all of them as a file.
02

Study summary

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Myeloproliferative Neoplasms
  • Myelofibrosis

Keywords

  • MDS
  • MF
  • MPN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily sign the form (ICF);
  • Age ≥ 18 years, either male or female;
  • (ECOG) performance status 0-2;
  • Expected is greater than 24 weeks;
  • Diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) according to World Health Organization (WHO);
  • The patients understands the purpose of and procedures required for the study and is willing to participate in the study;

Exclusion criteria

Exclusion Criteria:

  • Subjects with congestive heart failure, uncontrolled or unstable angina or myocardial infarction,cerebrovascular accident, or pulmonary embolism within 6 months prior to screening;
  • Subjects suffering from arrhythmia and requiring treatment, or > 480ms at screening;
  • Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal infections requiring treatment at screening;
  • Subjects with known (HIV), known active infectious (HepB), and/or known active infectious (HepC);
  • Female subjects who are pregnant, currently breastfeeding, planning to become pregnant;
  • Subjects who had experienced malignant tumors (except for adequately treated local basal cell or squamous cell carcinoma of the skin and cervical carcinoma in situ that have been cured) within the past 5 years;
  • Subjects who have any other conditions that are not specified in the protocol but the investigator believes that they are not suitable for inclusion in this trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Treatment(Jaktinib+Azacitidine)

    Patients receive azacitidine subcutaneously (SC) on days 1-7 and Jaktinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Jaktinib · Drug: azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (complete remission+partial remission+marrow compete remission +cytogenetic complete remission + hematological improvement) in patients with Myelodysplastic Syndromes

    According to the 2006 International Working Group (IWG) response criteria in myelodysplasia,The objective response rate will be estimated along with the Bayesian 95% credible interval.

    Time frame: Up to16 weeks

  2. Objective response rate (complete remission+cytogenetic complete remission+partial remission+clinical improvement) in patients with myelodysplastic syndromes/myeloproliferative neoplasms

    According to the 2015 ICP in MDS/MPN. The objective response rate will be estimated along with the Bayesian 95% credible interval.

    Time frame: Up to16 weeks

Secondary outcomes

  1. Overall survival

    Will be listed and summarized by the Kaplan-Meier estimator

    Time frame: Time from treatment start till death or last follow-up, assessed up to 2 years

  2. Duration of response

    Will be listed and summarized by the Kaplan-Meier estimator

    Time frame: Duration from the first documented onset of partial response or complete response to the date of progressive disease/relapse, assessed up to 2 years

  3. Relapse-free survival

    Will be listed and summarized by the Kaplan-Meier estimator

    Time frame: Time from start of response to the date of event defined as the first documented progressive disease/relapse or death, whichever comes first, assessed up to 2 years

07

Study locations

1 site
  • 79 Qingchun Road
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jun 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2021
First posted
Apr 29, 2021
StartActual
Sep 30, 2021
Primary completionActual
Jun 10, 2022
CompletionActual
Jun 10, 2022
Last update
Dec 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04866056
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Sep 30, 2021
Primary completion
Jun 10, 2022
Completion
Jun 10, 2022
Last update
Dec 1, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion